Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03610945 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03610945 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT03610945, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of fluconazole or quinidine on the pharmacokinetics and safety of EDP-305 in healthy human volunteers.
Interventions
- DRUG Fluconazole
- DRUG Quinidine
- DRUG EDP-305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-07-19 |
| Est. Completion | 2018-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03610945
The ClinicalTrials.gov registry entry for NCT03610945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluconazole is the first listed.
NCT03610945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03610945 about?
NCT03610945 is a clinical study titled "Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers". This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of fluconazole or quinidine on the pharmacokinetics and safety of EDP-305 in healthy human volunteers.
What is the current status of trial NCT03610945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-07-19. Estimated completion is 2018-08-21.
What interventions are being tested in trial NCT03610945?
The interventions under investigation include: Fluconazole (DRUG), Quinidine (DRUG), EDP-305 (DRUG).
Who is sponsoring clinical trial NCT03610945?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.